ライフサイエンスコーパス: once-daily

1 or (90 mg twice daily) or clopidogrel (75 mg once daily).

2 onthly) or subcutaneous teriparatide (20 mug once daily).

3 e fellow eye began topical bimatoprost 0.03% once daily.

4 olled and received savolitinib 600 mg orally once daily.

5 ir 30 mg plus abacavir-lamivudine 600-300 mg once daily.

6 ommended phase 2 dose was selected as 100 mg once daily.

7 zin (at a dose of 10 mg or 25 mg) or placebo once daily.

8 eceive 12 or 16 weeks of G/P (300 mg/120 mg) once daily.

9 tio to receive niraparib (300 mg) or placebo once daily.

10 enib 150 mg twice daily plus trametinib 2 mg once daily.

11 of resveratrol, 125 or 500 mg/d, or placebo once daily.

12 Patients self-administered masked capsules, once daily, 1 h before breakfast during the treatment ph

13 Once-daily 10 mg/kg iv treatment on days 3-14 postinfect

14 gned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224

15 ucted to assess the efficacy and safety of a once-daily, 2-direct-acting-antiviral-agent (2-DAA) comb

16 evels of imatinib mesylate, including 400 mg once daily (400 mg/d) vs 400 mg twice daily (800 mg/d),

17 iotherapy (up to 50.4 Gy; 28 doses of 1.8 Gy once daily, 5 days per week for up to 6.5 weeks) or dose

18 allocated participants (2:1) to receive oral once-daily 75 mg bictegravir or 50 mg dolutegravir with

19 ABT-493 plus 120 mg ABT-530 with or without once-daily 800 mg RBV for 12 weeks; treatment-experience

20 onths and 10 mg/kg in toddlers, administered once daily, achieved CFR >/= 90%, with <10% achieving li

21 randomly assigned to LAI (590 mg) or placebo once daily added to their multidrug regimen for 84 days.

22 f basimglurant MR (0.5 or 1.5 mg) or placebo once daily, adjunctive to ongoing antidepressant medicat

23 Here, we show that once daily administration of the novel glucose lowering

24 ADME profile met our selection criteria for once daily administration, targeting robust inhibition o

25 ance (arm B; concurrent), or cediranib 20 mg once-daily alongside chemotherapy then cediranib 20 mg o

26 ntenance (arm A; reference), cediranib 20 mg once-daily alongside chemotherapy then placebo only main

27 ratio to receive either 100 mg of tezacaftor once daily and 150 mg of ivacaftor twice daily or matche

28 in the phase 2 portion of this trial (90 mg once daily and 180 mg once daily with a 7 day lead-in at

29 also assessed two additional regimens (90 mg once daily and 180 mg once daily with a 7 day lead-in at

30 twice daily; 797 received study therapy, 531 once daily and 266 twice daily.

31 d in a ratio of 2:1 to AM-PQP (571 patients) once daily and artemether-lumefantrine (AL) (288 patient

32 ctive open-label trial of grazoprevir 100 mg once daily and elbasvir 50 mg once daily coadministered

33 had received 3-18 months of imatinib 400 mg once daily and had a suboptimal cytogenetic response acc

34 roup) or a basal-bolus regimen with glargine once daily and rapid-acting insulin lispro or aspart bef

35 macitentan, 10 mg of macitentan, or placebo once daily and stratified according to number of digital

36 ifty-two patients received sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12

37 d with grazoprevir (NS3/4A inhibitor; 100 mg once daily) and an NS5A inhibitor, either elbasvir (50 m

38 Morning administration of atazanavir (300 mg once daily) and darunavir regimens exhibited no clinical

39 one cohort] to 25 mg [in all other cohorts] once daily) and oral dexamethasone (40 mg weekly).

40 ndomization between doxycycline (200 mg/day, once daily) and placebo was performed in the medication

41 c (75 mg twice daily) plus omeprazole (20 mg once daily), and either rifaximin-EIR (400 mg) or placeb

42 0 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and to evaluate the safety and tolerability

43 340 to receive aliskiren at a dose of 300 mg once daily, and 2340 to receive both treatments (combina

44 at 150 mg twice daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) and warfar

45 at 150 mg twice daily, rivaroxaban at 20 mg once daily, and apixaban at 5 mg twice daily) compared w

46 450 mg/ritonavir 30 mg + JNJ-56914845 30 mg once daily (Arm 1: n = 22; GT1a/GT1b) or 60 mg once dail

47 ce daily (Arm 1: n = 22; GT1a/GT1b) or 60 mg once daily (Arm 2: n = 22; GT1a/GT1b).

48 Three mg/kg of elemental iron once daily as either ferrous sulfate drops or iron polys

49 We initially chose a dose of 180 mg once daily as the recommended phase 2 dose; however, we

50 Patients received endoxifen once daily at seven dose levels (20 to 160 mg).

51 Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adu

52 ts) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind,

53 ly treated patients with OHT or OAG received once-daily bimatoprost 0.01 % for 12 weeks.

54 r placebo or one of two fixed doses of oral, once-daily bitopertin (10 or 20 mg in TwiLyte and NightL

55 Abiraterone acetate, 1000 mg, once daily by mouth with prednisone, 5 mg, by mouth twic

56 ng metformin and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, o

57 oprevir 100 mg once daily and elbasvir 50 mg once daily coadministered with weight-based ribavirin tw

58 wice daily plus trametinib at a dose of 2 mg once daily (combination therapy, 438 patients) or two ma

59 ncurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients).

60 comes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with

61 e daily, or D 150 mg twice a day plus T 2 mg once daily (D + T 150/2).

62 dalteparin at a dose of 150 IU per kilogram once daily (dalteparin group).

63 xenatide 2 mg by subcutaneous injection plus once-daily dapagliflozin 10 mg oral tablets, exenatide w

64 oinfected patients received 8 or 12 weeks of once-daily DCV 60 mg (dose-adjusted as-necessary for con

65 Injection at least once daily declined from 45.2% to 18.8% (P < .001) and f

66 assessed the safety and efficacy of a 60-mg once-daily dosage of daclatasvir (pan-genotypic NS5A inh

67 A once-daily dosage of ledipasvir/sofosbuvir was similarly

68 In view of its once-daily dose and favourable safety profile, WTX101 co

69 in HIV-1 RNA were similar for the 40-120 mg once-daily dose groups regardless of baseline Gag polymo

70 itor of Bruton's tyrosine kinase (BTK), at a once-daily dose of 420 mg achieved BTK active-site occup

71 Treatment with a 50-mg once-daily dose of opicapone was associated with a signi

72 r dose-expansion cohorts assigned to receive once-daily doses of oral gilteritinib (20 mg, 40 mg, 80

73 -to-oral solithromycin or moxifloxacin for 7 once-daily doses.

74 half-life of 12-48 h is generally ideal for once daily dosing of oral drugs.

75 n a higher serum hepcidin concentration than once-daily dosing (p=0.013).

76 Ten women were assigned to receive once-daily dosing and ten were assigned to receive twice

77 NaC-transgenic mice to greater than 90% with once-daily dosing by inhalation.

78 domized, double-masked trials reported here, once-daily dosing of netarsudil 0.02% was found to be ef

79 izophrenia were randomly assigned to receive once-daily dosing with 10 mg of ABT-126, 25 mg of ABT-12

80 Chronic steroid use usually involves once-daily dosing, although weekly dosing in children ha

81 e of thromboprophylaxis (heparin, enoxaparin once-daily dosing, early ambulation), hospital discharge

82 okinetic (PK) profile that was predictive of once-daily dosing.

83 botegravir 30 mg tablets or matching placebo once daily during a 4 week oral lead-in phase, followed

84 care plus oral regorafenib 160 mg or placebo once daily during weeks 1-3 of each 4-week cycle.

85 followed by oral edoxaban at a dose of 60 mg once daily (edoxaban group) or subcutaneous dalteparin a

86 Patients were given an oral, once-daily, fixed-dose combination of EBR/GZR 50 mg/100

87 ) continued twice daily fluticasone (F), (2) once daily fluticasone plus salmeterol (F + S), or (3) o

88 a dose of 200 IU per kilogram of body weight once daily for 1 month followed by dalteparin at a dose

89 ts received 5-120 mg GSK3532795 (or placebo) once daily for 10 days.

90 standard-dose subcutaneous enoxaparin (40 mg once daily for 10+/-4 days) for venous thromboprophylaxi

91 meprevir 150 mg once daily+sofosbuvir 400 mg once daily for 12 or 8 weeks.

92 Patients received LDV/SOF (90-400 mg) once daily for 12 to 24 weeks with or without ribavirin

93 patients) or matching placebo (150 patients) once daily for 12 weeks.

94 with pibrentasvir (120 mg) was administered once daily for 12 weeks.

95 All patients received sofosbuvir-velpatasvir once daily for 12 weeks.

96 previr 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks.

97 ceive PF-00489791 (20 mg) or placebo orally, once daily for 12 weeks.

98 tablet of ledipasvir-sofosbuvir (90/400 mg) once daily for 12 weeks.

99 et of 90 mg ledipasvir and 400 mg sofosbuvir once daily for 12 weeks.

100 standard therapy plus STS injection (80 mg, once daily for 14 consecutive days).

101 nd lamivudine 300 mg, with matching placebo, once daily for 144 weeks.

102 in placebo (isocaloric dose, controls; n=20) once daily for 16 weeks.

103 or dose-dense oral temozolomide (75 mg/m(2) once daily for 21 days, repeated every 28 days [one cycl

104 50 mg, or CPP-1X 750 mg and sulindac placebo once daily for 24 months.

105 zanimod (0.5 mg or 1 mg) or matching placebo once daily for 24 weeks by an independent, unmasked, sta

106 eceive oral 10 mg/kg azithromycin or placebo once daily for 3 days, followed by serotype-3 monovalent

107 her extended-duration oral betrixaban (80 mg once daily for 35-42 days) or standard-dose subcutaneous

108 roups received 90-min air pressure exposures once daily for 5 days per week for a total of 8 weeks (t

109 blets (n = 199) or matched placebo (n = 202) once daily for 5 days.

110 All patients received ledipasvir-sofosbuvir once daily for 6 weeks.

111 ixed-dose combination) plus GS-9857 (100 mg) once daily for 6-12 weeks, plus ribavirin for 1 treatmen

112 ose combination tablet) and GS-9857 (100 mg) once daily for 6-12 weeks.

113 il fumarate (300 mg), with matching placebo, once daily for 96 weeks.

114 sults support the use of raltegravir 1200 mg once daily for first-line therapy.

115 adiation and healing (UVB doses 1.01 J/cm(2) once daily for four days).

116 intervention group will receive UDCA 900 mg once daily for six months.

117 fentanyl concentrations in plasma collected once daily for up to 5 days after enrollment.

118 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d.

119 f ledipasvir and 400 mg of sofosbuvir orally once-daily for 12 weeks.

120 subcutaneous enoxaparin (at a dose of 40 mg once daily) for 10+/-4 days plus oral betrixaban placebo

121 ays plus oral betrixaban (at a dose of 80 mg once daily) for 35 to 42 days.

122 0 mg) followed by oral spironolactone (25 mg once daily) for 6 months in addition to standard therapy

123 Empirical treatment with micafungin (100 mg, once daily, for 14 days) (n = 131) vs placebo (n = 129).

124 im-sulfamethoxazole or placebo taken orally, once daily, for 2 years.

125 disoproxil fumarate and emtricitabine orally once daily, for up to 96 weeks.

126 We compared a new once daily formulation of raltegravir to the currently m

127 tions of 1.5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on d

128 sponse system to dapagliflozin 5 mg or 10 mg once daily, given orally, or matched placebo.

129 sults show that 99% of patients treated with once-daily glecaprevir plus pibrentasvir achieved a sust

130 rred in 130 (24%) of 531 participants in the once daily group (one of which was serious; none led to

131 e-daily group (hazard ratio for death in the once daily group 1.18 [95% CI 0.95-1.45]; p=0.14).

132 the twice-daily group and 51% (45-57) in the once-daily group (absolute difference between the treatm

133 -daily group versus 25 months (21-31) in the once-daily group (hazard ratio for death in the once dai

134 2% higher overall survival at 2 years in the once-daily group versus the twice-daily group was consid

135 ne in the twice-daily group and three in the once-daily group) did not return their case report forms

136 twice-daily group vs 170 [65%] of 263 in the once-daily group).

137 ee in the twice-daily group and eight in the once-daily group).

138 twice-daily group vs 47 [19%] of 246 in the once-daily group; p=0.85) and grade 3-4 radiation pneumo

139 both intravenous and oral formulations dosed once daily, has completed 2 global phase 3 trials for tr

140 aneous injections of elamipretide (0.5 mg/kg once daily, HF+ELA, n=7) or saline (control, HF-CON, n=7

141 h predicted human PK properties suitable for once daily human dosing.

142 a and hyperglycaemia in one patient on 60 mg once daily, hyperglycaemia in one patient on 150 mg twic

143 These results support sustained adherence to once-daily ibrutinib dosing at 420 mg as clinically feas

144 lozin 10 mg, empagliflozin 25 mg, or placebo once daily in addition to standard of care.

145 ed the pharmacokinetics of rilpivirine 25 mg once daily in HIV-1-infected women during late pregnancy

146 myeloid leukaemia received oral gilteritinib once daily in one of seven dose-escalation (n=23) or dos

147 ith acalabrutinib at a dose of 100 to 400 mg once daily in the dose-escalation (phase 1) portion of t

148 nts randomized to TRAV+TIM administered TRAV once daily in the evening and TIM once daily in the morn

149 TTFC was administered once daily in the morning or evening with a single dosin

150 tered TRAV once daily in the evening and TIM once daily in the morning using separate dosing aids.

151 0 mg twice daily) plus oral trametinib (2 mg once daily) in continuous 21-day cycles until disease pr

152 ndomly assigned to initiate treatment with a once-daily inhaled combination of either 100 mug or 200

153 ndomly assigned 2799 patients with COPD to a once-daily inhaled combination of fluticasone furoate at

154 a double-blind, randomized controlled trial, once-daily inhaled placebo, fluticasone furoate (FF; 100

155 r corticosteroids were randomised to receive once daily, inhaled budesonide 400 mug (those aged <11 y

156 inistration of bictegravir, a novel, potent, once-daily INSTI designed to improve on existing INSTI o

157 Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine

158 Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine

159 ollowing a fixed dose-escalation regimen) or once-daily insulin glargine (starting dose 10 IU per day

160 We sought to examine the effects of a 6-wk once-daily intake of dietary nitrate (nitrate-rich beetr

161 Dolutegravir is a once-daily integrase strand transfer inhibitor with no n

162 mtricitabine, and tenofovir alafenamide is a once-daily, integrase strand transfer inhibitor-based re

163 pants were sequentially assigned as follows: once daily, intermittently (twice or three times weekly;

164 Once daily intramuscular (i.m.) injection for 3 d would

165 In a rhesus monkey model of EVD, once-daily intravenous administration of 10 mg kg(-1) GS

166 3 times daily for 2 days followed by 200 mg once-daily (IV or PO).

167 or (250 mg every 12 h) or lumacaftor (600 mg once daily)/ivacaftor (250 mg every 12 h).

168 and safety profile of the lumacaftor 600 mg once daily/ivacaftor 250 mg every 12 h groups was genera

169 Once-daily lithium dosing and maintaining lower lithium

170 on COPD Exacerbations) study, which compared once-daily long-acting beta2-agonist/long-acting muscari

171 INTERPRETATION: In mild recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, red

172 In mild recent-onset asthma, once daily, low-dose budesonide decreases SARE risk, red

173 Once daily, low-dose ferrous sulfate should be considere

174 he effects of two doses of elagolix - 150 mg once daily (lower-dose group) and 200 mg twice daily (hi

175 alongside chemotherapy then cediranib 20 mg once-daily maintenance (arm C; maintenance).

176 these results suggest that rilpivirine 25 mg once daily may be an alternative treatment option for HI

177 m ten were sequentially assigned to CUDC-907 once-daily (MTD 60 mg), 12 to twice-weekly (MTD 150 mg),

178 andomly assigned to receive dasatinib 100 mg once daily (n = 259) or imatinib 400 mg once daily (n =

179 0 mg once daily (n = 259) or imatinib 400 mg once daily (n = 260).

180 To demonstrate the efficacy and safety of once-daily nepafenac 0.3% ophthalmic suspension versus v

181 or) in combination with sofosbuvir at 400 mg once daily (NS5B inhibitor) and ribavirin at 600 mg/day

182 he efficacies of two doses (300 mg or 450 mg once daily) of uprifosbuvir (MK-3682; NS5B inhibitor) in

183 oral tablets, twice daily on days 1-5, then once daily on alternate days on days 7-25) or vancomycin

184 We chose ricolinostat 160 mg once daily on days 1-21 of a 28 day cycle as the recomme

185 21-day cycle, plus lapatinib 1250 mg orally once daily on days 1-21).

186 ed to test the effects of pravastatin (40 mg once daily) on cardiovascular risk.

187 to one of six tenapanor regimens (3 or 30 mg once daily or 1, 3, 10, or 30 mg twice daily) or placebo

188 tients at doses ranging from 10 mg to 200 mg once daily or 35 mg to 100 mg twice daily, with a minimu

189 ith escalating dosages of BGJ398 5 to 150 mg once daily or 50 mg twice daily continuously in 28-day c

190 ection received either AM-PQP (714 patients) once daily or artemether-lumefantrine (A-L; 358 patients

191 gned (2:1) to receive oral pacritinib 400 mg once daily or best available therapy (BAT) excluding JAK

192 a dopamine agonist that can be administered once daily or by transdermal patch seems to be a reasona

193 a dopamine agonist that can be administered once daily or by transdermal patch.

194 trial that investigated tinzaparin 175 IU/kg once daily or dose-adjusted warfarin for 6 months in pat

195 n, and either oral vandetanib 300 mg per day once daily or matching placebo.

196 f myocardial infarction to pravastatin 40 mg once daily or placebo for 5 years.

197 were randomized to receive pravastatin 40 mg once daily or placebo for an average of 4.9 years.

198 mly assigned 2:1 to anamorelin 100 mg orally once daily or placebo, with a computer-generated randomi

199 tegravir 1200 mg (two 600 mg tablets) orally once daily or raltegravir 400 mg (one tablet) orally twi

200 subjects received 40 mg or 120 mg GSK3532795 once daily (or placebo) for 10 days.

201 receive second-line oral buparlisib (100 mg once daily) or placebo, plus intravenous paclitaxel (80

202 nd an NS5A inhibitor, either elbasvir (50 mg once daily) or ruzasvir (MK-8408; 60 mg once daily), and

203 1 and 2, then either intravenously or orally once daily) or voriconazole (6 mg/kg intravenously twice

204 rly every 28 days), everolimus (10 mg orally once daily), or both in combination, for the core 12-mon

205 wice a day, D 150 mg twice a day plus T 1 mg once daily, or D 150 mg twice a day plus T 2 mg once dai

206 n interactive web-response system to receive once daily oral amiselimod 0.1 mg, 0.2 mg, 0.4 mg, or pl

207 P-glycoprotein inhibitors in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared Wit

208 Once daily oral dosing of LY2940094 at 40 mg for 8 weeks

209 fluticasone plus salmeterol (F + S), or (3) once daily oral montelukast (M).

210 Participants were randomized 1:1:1:1 to a once-daily oral dose of GSK1278863 (0.5 mg, 2 mg, or 5 m

211 on and previous treatment status, to receive once-daily oral doses of tenofovir alafenamide 25 mg or

212 efficacy of an 8-week treatment duration of once-daily oral ombitasvir 25 mg, paritaprevir 150 mg, a

213 Once-daily oral semaglutide of 2.5 mg (n = 70), 5 mg (n

214 points from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared W

215 or pravastatin 40 mg with matching placebos once daily orally for 12 weeks, followed by a 40 week sa

216 [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatas

217 We applied detrended fluctuation analysis to once-daily PEF data from 493 participants in the LOCCS (

218 s were randomly assigned in a 1:1:1 ratio to once-daily placebo, valbenazine at 40 mg/day, or valbena

219 atment with opicapone (5 mg, 25 mg, or 50 mg once daily), placebo, or entacapone (200 mg with every l

220 y assigned to receive 20 mug of teriparatide once daily plus oral weekly placebo or 35 mg of oral ris

221 n a 1:1:1 ratio, low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months (group

222 y with a dose-adjusted vitamin K antagonist (once daily) plus DAPT for 1, 6, or 12 months (group 3).

223 :1:1) to receive placebo, lumacaftor (600 mg once daily) plus ivacaftor (250 mg every 12 h), or lumac

224 o placebo (497) or nepafenac 0.3% (503) used once daily, post-operatively for 5 weeks at two ophthalm

225 Edoxaban once daily provides an attractive alternative to warfari

226 were randomized to receive netarsudil 0.02% once daily (q.d.), timolol 0.5% twice a day (b.i.d.), an

227 >/=14%, and plasma HIV-1 RNA suppression on once-daily (QD) DRV-containing ART at screening.

228 he trial was designed to show superiority of once-daily radiotherapy and was not powered to show equi

229 INTERPRETATION: A once daily raltegravir 1200 mg regimen was non-inferior

230 (arm A), 300 mg GLE + 120 mg PIB with 800 mg once-daily RBV (arm B), or 300 mg GLE + 120 mg PIB witho

231 At week 48, 472 (89%) of 531 once daily recipients and 235 (88%) of 266 twice daily r

232 The once-daily recommended dose for oral, single agent oral

233 The once-daily recommended dose for oral, single agent oral

234 cally significant to show superiority of the once-daily regimen.

235 Once daily regimens are preferred for HIV-1 treatment, t

236 se 2 expansion stage, we assessed three oral once-daily regimens: 90 mg, 180 mg, and 180 mg with a 7

237 TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1200 mg/day; Panel 2-Arm 2 (

238 The once-daily, ribavirin-free, pangenotypic, direct-acting

239 meprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg once daily + ribavirin 1000-1

240 ith venous thromboembolism to receive either once-daily rivaroxaban (at doses of 20 mg or 10 mg) or 1

241 3 or more months were equally randomized to once-daily roflumilast, 500 mug (n = 1,178), or placebo

242 Dosing started at 30 mg for the once-daily schedule and 60 mg for other schedules, escal

243 These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1

244 No once-daily single-tablet regimen is available for HIV-in

245 of cirrhosis received oral simeprevir 150 mg once daily + sofosbuvir 400 mg once daily for 12 weeks.

246 IL28B GT [CC, non-CC]) to simeprevir 150 mg once daily+sofosbuvir 400 mg once daily for 12 or 8 week

247 ages: placebo, ABT-126 25 mg, 50 mg or 75 mg once daily (stage 1) and placebo or ABT-126 50 mg (stage

248 d (1:1) to topical nepafenac 0.3% or vehicle once-daily starting the day before surgery and continuin

249 the phase 2 BOLD (BAF312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclero

250 Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or plac

251 1, using a telephone or web-based system, to once-daily subcutaneous liraglutide 3.0 mg or matched pl

252 ipants were randomized to imiquimod 5% cream once daily (superficial basal cell carcinoma, 6 weeks; n

253 ssess patient adherence to and acceptance of once-daily tacrolimus (Advagraf) initiation in kidney an

254 Data from 1106 patients initiating once-daily tacrolimus during posttransplant follow-up we

255 For 94.9% of patients, once-daily tacrolimus was prescribed after switching fro

256 , South Africa, initiating ART in pregnancy (once-daily tenofovir 300 mg, emtricitabine 200 mg, and e

257 ceive either sitagliptin plus basal glargine once daily (the sitagliptin-basal group) or a basal-bolu

258 ce daily until age 6 months and 200 mg/40 mg once daily thereafter) or placebo from age 14-34 days to

259 ged 6 to 11 years were randomized to receive once-daily tiotropium 5 mug (2 puffs of 2.5 mug) or 2.5

260 2.5 mug) or 2.5 mug (2 puffs of 1.25 mug) of once-daily tiotropium or placebo (2 puffs) administered

261 Once-daily tiotropium Respimat 5 mug improved lung funct

262 sought to assess the efficacy and safety of once-daily tiotropium Respimat add-on therapy to high-do

263 sought to assess the efficacy and safety of once-daily tiotropium Respimat added to ICSs with or wit

264 nel 2-Arm 1 (n = 12; GT1b): simeprevir 75 mg once daily + TMC647055 450 mg once daily/ritonavir 30 mg

265 We gave escalating doses (from 40-240 mg once daily to 160 mg twice daily) of oral ricolinostat a

266 llowed to choose whether to stop or continue once-daily topical corticosteroids to maximize complianc

267 were enrolled and randomly assigned, 533 to once daily treatment and 269 to twice daily; 797 receive

268 Once daily treatment with the small molecule SIK inhibit

269 maintenance inhaler therapy, initiation of a once-daily treatment regimen of combined fluticasone fur

270 d, antiretroviral therapy-naive men starting once-daily treatment with DTG (50 mg) plus abacavir-lami

271 tion of lung edema, indicating potential for once-daily treatment.

272 or therapy received osimertinib 80 mg orally once daily; treatment could continue beyond progression

273 nd, double-dummy study comparing 24 weeks of once-daily triple therapy (fluticasone furoate/umeclidin

274 We compared the effects of once-daily triple therapy on lung function and health-re

275 Bictegravir, a novel, once-daily, unboosted INSTI, showed potent activity in a

276 gned to receive co-trimoxazole (100 mg/20 mg once daily until age 6 months and 200 mg/40 mg once dail

277 travenous ganciclovir or oral valganciclovir once daily until hospital discharge (n = 84) or to recei

278 Patients received oral ibrutinib 420 mg once daily until progression or unacceptable toxicity.

279 en were treated with 560 mg ibrutinib orally once daily until progression or unacceptable toxicity.

280 lapsed or refractory NHL received venetoclax once daily until progressive disease or unacceptable tox

281 ytic lymphoma received oral ibrutinib 420 mg once daily until progressive disease or unacceptable tox

282 Once-daily valbenazine significantly improved tardive dy

283 Following taper to once-daily vancomycin dosing, 22 of 36 patients (61%) wh

284 Patients started once daily venetoclax with a weekly dose ramp-up schedul

285 were treated in randomized order with 100 mg once daily vildagliptin or placebo for 10 days.

286 l (day 1-3 geometric mean: 11.8% [7.1, 19.4] once daily vs 13.1% [8.2, 20.7] twice daily; p=0.33) or

287 on absorption (day 1-3: 44.3 mg [29.4, 66.7] once daily vs 49.4 [35.2, 69.4] twice daily; p=0.33) bet

288 Enasidenib 100 mg once daily was selected for the expansion phase on the b

289 l movement, having bowel movements more than once daily was significantly associated with increased r

290 d pregnant women receiving rilpivirine 25 mg once daily were included.

291 tional regimens (90 mg once daily and 180 mg once daily with a 7 day lead-in at 90 mg) in the phase 2

292 n of this trial (90 mg once daily and 180 mg once daily with a 7 day lead-in at 90 mg).

293 subjects received 40 mg or 80 mg GSK3532795 once daily with atazanavir (ATV) with or without (+/-) r

294 with either 6 or 18 mg of selonsertib orally once daily with or without once-weekly injections of 125

295 Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily was admini

296 Mice were treated once daily with vehicle alone or BI-BTK-1, either prophy

297 Sunitinib (50 mg) was given orally once daily, with each cycle defined as 4 weeks on treatm

298 sofosbuvir (400 mg) (ledipasvir/sofosbuvir) once daily, with or without ribavirin twice daily.

299 d rosuvastatin for 2 years, starting at 5 mg once daily, with uptitration to 10 mg (age, 6-<10 years)

300 r, 150 mg paritaprevir, and 100 mg ritonavir once daily, with weight-based ribavirin dosed twice dail